Wei-Chang Chen1, Qiang Liu, Jian-Xin Fu, Su-Ya Kang. 1. Department of Gastroenterology, The First Affiliated Hospital of Suzhou University, Suzhou 215006, Jiangsu Province, China. cwc-sz@hotmail.com
Abstract
AIM: To study the expression of survivin, a novel member of inhibitors of apoptosis protein (IAP) and its significance in colorectal carcinoma. METHODS: Survivin mRNA expression was evaluated by semi-quantitative reverse transcriptase polymerase chain reaction (RT-PCR) in 52 colorectal carcinoma samples and 48 adjacent normal colorectal tissue samples. PCR product was sequenced to verify the desired result. Expressions of survivin protein, proliferating cell nuclear antigen labelling index (PI) and apoptotic index (AI) were detected immunohistochemically in 52 human colorectal carcinomas. RESULTS: The expression of survivin mRNA was detected in a significantly greater proportion of colorectal carcinoma samples than in adjacent normal colorectal tissues (67.3% vs 25%; P<0.01). There was no relationship between survivin mRNA expression in colorectal carcinomas and sex, tumor size, histological types, lymphnode metastasis, distant metastasis and Dukes' stage. The PCR product shared 99% of homology with human counterparts. Survivin expression was observed immunohistochemically in 27 of 52 cases of colorectal carcinoma (51.9%). The AI was significantly lower in survivin positive group than in survivin negative group (0.67+/-0.18% vs 1.14+/-0.42%; P<0.001), while the PI was greater in survivin positive group than in survivin negative group (51+/-22% vs 27+/-18%, P<0.001). CONCLUSION: Survivin is a special tumor marker independent of histopathological characteristics. It may play an important role during human colorectal tumorigenesis by inhibiting apoptosis and accelerating proliferative activity of colorectal tumor cells.
AIM: To study the expression of survivin, a novel member of inhibitors of apoptosis protein (IAP) and its significance in colorectal carcinoma. METHODS: Survivin mRNA expression was evaluated by semi-quantitative reverse transcriptase polymerase chain reaction (RT-PCR) in 52 colorectal carcinoma samples and 48 adjacent normal colorectal tissue samples. PCR product was sequenced to verify the desired result. Expressions of survivin protein, proliferating cell nuclear antigen labelling index (PI) and apoptotic index (AI) were detected immunohistochemically in 52 humancolorectal carcinomas. RESULTS: The expression of survivin mRNA was detected in a significantly greater proportion of colorectal carcinoma samples than in adjacent normal colorectal tissues (67.3% vs 25%; P<0.01). There was no relationship between survivin mRNA expression in colorectal carcinomas and sex, tumor size, histological types, lymphnode metastasis, distant metastasis and Dukes' stage. The PCR product shared 99% of homology with human counterparts. Survivin expression was observed immunohistochemically in 27 of 52 cases of colorectal carcinoma (51.9%). The AI was significantly lower in survivin positive group than in survivin negative group (0.67+/-0.18% vs 1.14+/-0.42%; P<0.001), while the PI was greater in survivin positive group than in survivin negative group (51+/-22% vs 27+/-18%, P<0.001). CONCLUSION: Survivin is a special tumor marker independent of histopathological characteristics. It may play an important role during human colorectal tumorigenesis by inhibiting apoptosis and accelerating proliferative activity of colorectal tumor cells.
Authors: D S O'Connor; D Grossman; J Plescia; F Li; H Zhang; A Villa; S Tognin; P C Marchisio; D C Altieri Journal: Proc Natl Acad Sci U S A Date: 2000-11-21 Impact factor: 11.205
Authors: A Krieg; C Mahotka; T Krieg; H Grabsch; W Müller; S Takeno; C V Suschek; M Heydthausen; H E Gabbert; C D Gerharz Journal: Br J Cancer Date: 2002-03-04 Impact factor: 7.640
Authors: Dermot T McDowell; Fraser M Smith; John V Reynolds; Stephen G Maher; Collette Adida; Paul Crotty; Eoin F Gaffney; Donal Hollywood; Brian Mehigan; Richard B Stephens; M J Kennedy Journal: Int J Colorectal Dis Date: 2009-07-11 Impact factor: 2.571
Authors: John A Ronald; Hui-Yen Chuang; Anca Dragulescu-Andrasi; Sharon S Hori; Sanjiv S Gambhir Journal: Proc Natl Acad Sci U S A Date: 2015-02-23 Impact factor: 11.205
Authors: B-C Ahn; J A Ronald; Y I Kim; R Katzenberg; A Singh; R Paulmurugan; S Ray; L V Hofmann; S S Gambhir Journal: Gene Ther Date: 2011-02-10 Impact factor: 5.250
Authors: Anastasia Pavlidou; Maria Dalamaga; Christos Kroupis; George Konstantoudakis; Maria Belimezi; George Athanasas; Kleanthi Dimas Journal: World J Gastroenterol Date: 2011-03-28 Impact factor: 5.742
Authors: Peter C Konturek; Kazimierz Rembiasz; Grzegorz Burnat; Stanisław J Konturek; Marcin Tusinela; Władysław Bielanski; Jens Rehfeld; Danuta Karcz; Eckhart Hahn Journal: Dig Dis Sci Date: 2006-04 Impact factor: 3.199
Authors: Ashish Saxena; Mohammad Shoeb; Ravinder Tammali; Kota V Ramana; Satish K Srivastava Journal: Cancer Lett Date: 2014-09-10 Impact factor: 8.679
Authors: Tatyana Zykova; Feng Zhu; Lei Wang; Haitao Li; Do Young Lim; Ke Yao; Eunmiri Roh; Sang-Pil Yoon; Hong-Gyum Kim; Ki Beom Bae; Weihong Wen; Seung Ho Shin; Janos Nadas; Yan Li; Weiya Ma; Ann M Bode; Zigang Dong Journal: Mol Cancer Ther Date: 2018-02-26 Impact factor: 6.261